106 related articles for article (PubMed ID: 17661420)
1. Determining the model for end-stage liver disease with better accuracy: neutralizing the international normalized ratio pitfalls.
Marlar RA
Hepatology; 2007 Aug; 46(2):295-6. PubMed ID: 17661420
[No Abstract] [Full Text] [Related]
2. How to implement the modified international normalized ratio for cirrhosis (INR(liver)) for model for end-stage liver disease calculation.
Tripodi A
Hepatology; 2008 Apr; 47(4):1423-4; author reply 1424. PubMed ID: 18306415
[No Abstract] [Full Text] [Related]
3. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease.
Tripodi A; Caldwell SH; Hoffman M; Trotter JF; Sanyal AJ
Aliment Pharmacol Ther; 2007 Jul; 26(2):141-8. PubMed ID: 17593061
[TBL] [Abstract][Full Text] [Related]
4. Selecting an optimal prognostic system for liver cirrhosis: the model for end-stage liver disease and beyond.
Huo TI; Lee SD; Lin HC
Liver Int; 2008 May; 28(5):606-13. PubMed ID: 18433390
[TBL] [Abstract][Full Text] [Related]
5. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis.
Luca A; Angermayr B; Bertolini G; Koenig F; Vizzini G; Ploner M; Peck-Radosavljevic M; Gridelli B; Bosch J
Liver Transpl; 2007 Aug; 13(8):1174-80. PubMed ID: 17663415
[TBL] [Abstract][Full Text] [Related]
6. Comparison of four model for end-stage liver disease-based prognostic systems for cirrhosis.
Huo TI; Lin HC; Huo SC; Lee PC; Wu JC; Lee FY; Hou MC; Lee SD
Liver Transpl; 2008 Jun; 14(6):837-44. PubMed ID: 18508377
[TBL] [Abstract][Full Text] [Related]
7. International normalized ratio: towards improved accuracy.
van den Besselaar AM
Thromb Haemost; 1999 Dec; 82(6):1562-3. PubMed ID: 10613634
[No Abstract] [Full Text] [Related]
8. The prothrombin time-derived international normalized ratio: great for Warfarin, fair for prognosis and bad for liver-bleeding risk.
Caldwell S; Shah N
Liver Int; 2008 Dec; 28(10):1325-7. PubMed ID: 19055640
[No Abstract] [Full Text] [Related]
9. Noninvasive models to predict liver cirrhosis in patients with chronic hepatitis B.
Kim BK; Kim SA; Park YN; Cheong JY; Kim HS; Park JY; Cho SW; Han KH; Chon CY; Moon YM; Ahn SH
Liver Int; 2007 Sep; 27(7):969-76. PubMed ID: 17696936
[TBL] [Abstract][Full Text] [Related]
10. Model for end-stage liver disease, model for end-stage liver disease-sodium and Child-Turcotte-Pugh scores over time for the prediction of complications of liver cirrhosis.
Choi PC; Kim HJ; Choi WH; Park DI; Park JH; Cho YK; Sohn CI; Jeon WK; Kim BI
Liver Int; 2009 Feb; 29(2):221-6. PubMed ID: 18544124
[TBL] [Abstract][Full Text] [Related]
11. Clinically relevant differences in the model for end-stage liver disease and model for end-stage liver disease-sodium scores determined at three university-based laboratories of the same area.
Xiol X; Gines P; Castells L; Twose J; Ribalta A; Fuentes-Arderiu X; Rodriguez S; Castellote J; Navasa M; Deulofeu R
Liver Transpl; 2009 Mar; 15(3):300-5. PubMed ID: 19242993
[TBL] [Abstract][Full Text] [Related]
12. Inequities of the Model for End-Stage Liver Disease: an examination of current components and future additions.
Bambha KM; Biggins SW
Curr Opin Organ Transplant; 2008 Jun; 13(3):227-33. PubMed ID: 18685308
[TBL] [Abstract][Full Text] [Related]
13. Interaction of daptomycin with two recombinant thromboplastin reagents leads to falsely prolonged patient prothrombin time/International Normalized Ratio results.
Webster PS; Oleson FB; Paterson DL; Arkin CF; Mangili A; Craven DE; Adcock DM; Lindfield KC; Knapp AG; Martone WJ
Blood Coagul Fibrinolysis; 2008 Jan; 19(1):32-8. PubMed ID: 18180613
[TBL] [Abstract][Full Text] [Related]
14. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.
Murillas J; Rimola A; Laguno M; de Lazzari E; Rascón J; Agüero F; Blanco JL; Moitinho E; Moreno A; Miró JM;
Liver Transpl; 2009 Sep; 15(9):1133-41. PubMed ID: 19718643
[TBL] [Abstract][Full Text] [Related]
15. Indocyanine green clearance test and model for end-stage liver disease score of patients with liver cirrhosis.
Sheng QS; Lang R; He Q; Yang YJ; Zhao DF; Chen DZ
Hepatobiliary Pancreat Dis Int; 2009 Feb; 8(1):46-9. PubMed ID: 19208514
[TBL] [Abstract][Full Text] [Related]
16. Alanine aminotransferase/aspartate aminotransferase ratio reversal and prolonged prothrombin time: a specific indicator of hepatic cirrhosis.
Siddiqi AI; Siddiqeh M; Mehmood A; Siddiqui AM
J Ayub Med Coll Abbottabad; 2007; 19(3):22-4. PubMed ID: 18444585
[TBL] [Abstract][Full Text] [Related]
17. Interlaboratory variability in assessment of the model of end-stage liver disease score.
Lisman T; van Leeuwen Y; Adelmeijer J; Pereboom IT; Haagsma EB; van den Berg AP; Porte RJ
Liver Int; 2008 Dec; 28(10):1344-51. PubMed ID: 18482269
[TBL] [Abstract][Full Text] [Related]
18. External quality assessment of CoaguChek point-of-care testing prothrombin time/international ratio monitors.
Kitchen S; Kitchen D; Jennings I; Woods T; Walker I
Am J Clin Pathol; 2008 May; 129(5):825-6. PubMed ID: 18481407
[No Abstract] [Full Text] [Related]
19. [How to prevent complications of liver cirrhosis?].
Adler M; Verset C; Moreno G
Rev Med Brux; 2007 Sep; 28(4):270-5. PubMed ID: 17958020
[TBL] [Abstract][Full Text] [Related]
20. Model for End-Stage Liver Disease (MELD) score system to evaluate patients with viral hepatitis on the waiting list: better than the Child-Turcotte-Pugh (CTP) system?
Cuomo O; Perrella A; Arenga G
Transplant Proc; 2008; 40(6):1906-9. PubMed ID: 18675085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
